These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 30951686)

  • 1. Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3.
    van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Blanco-Garavito R; Souied EH; Keunen JEE; MacLaren RE; Querques G; Fauser S; Downes SM; Hoyng CB; Boon CJF
    Am J Ophthalmol; 2019 Sep; 205():1-10. PubMed ID: 30951686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser.
    van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; Keunen JEE; MacLaren RE; Hoyng CB; Downes SM; Fauser S; Boon CJF
    Acta Ophthalmol; 2021 Nov; 99(7):805-811. PubMed ID: 33565230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial.
    van Dijk EHC; Fauser S; Breukink MB; Blanco-Garavito R; Groenewoud JMM; Keunen JEE; Peters PJH; Dijkman G; Souied EH; MacLaren RE; Querques G; Downes SM; Hoyng CB; Boon CJF
    Ophthalmology; 2018 Oct; 125(10):1547-1555. PubMed ID: 29776672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data.
    Subhi Y; Bjerager J; Boon CJF; van Dijk EHC
    Acta Ophthalmol; 2022 Feb; 100(1):89-95. PubMed ID: 33998168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy: The REPLACE Trial.
    van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; MacLaren RE; Downes SM; Fauser S; Boon CJF; Hoyng CB
    Am J Ophthalmol; 2020 Aug; 216():80-89. PubMed ID: 32289294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy.
    van Rijssen TJ; Singh SR; van Dijk EHC; Rasheed MA; Vupparaboina KK; Boon CJF; Chhablani J
    Graefes Arch Clin Exp Ophthalmol; 2020 Jun; 258(6):1191-1197. PubMed ID: 32170365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
    van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial.
    Breukink MB; Downes SM; Querques G; van Dijk EHC; den Hollander AI; Blanco-Garavito R; Keunen JEE; Souied EH; MacLaren RE; Hoyng CB; Fauser S; Boon CJF
    Trials; 2015 Sep; 16():419. PubMed ID: 26390920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
    Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
    Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RESPONSE OF CHOROIDAL ABNORMALITIES TO PHOTODYNAMIC THERAPY VERSUS MICROPULSE LASER IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Place Trial Report No. 4.
    van Rijssen TJ; Hahn LC; van Dijk EHC; Tsonaka R; Scholz P; Breukink MB; Blanco-Garavito R; Souied EH; Keunen JEE; MacLaren RE; Querques G; Fauser S; Downes SM; Hoyng CB; Boon CJF
    Retina; 2021 Oct; 41(10):2122-2131. PubMed ID: 34543244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing Half-Dose Photodynamic Therapy with Subthreshold Micropulse Laser for the Treatment of Central Serous Chorioretinopathy.
    Brelen ME; Ho M; Li S; Ng DSC; Yip YWY; Lee WS; Chen LJ; Young AL; Tham CC; Pang CP
    Ophthalmol Retina; 2024 May; 8(5):490-498. PubMed ID: 37956794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Early and Late Morphological and Functional Changes After Verteporfin Photodynamic Therapy.
    Iacono P; Tedeschi M; Boccassini B; Chiaravalloti A; Varano M; Parravano M
    Retina; 2019 May; 39(5):980-987. PubMed ID: 29346241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Son BK; Kim K; Kim ES; Yu SY
    Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK; Chang CK; Peng CH
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy.
    van Rijssen TJ; van Dijk EHC; Scholz P; MacLaren RE; Fauser S; Downes SM; Hoyng CB; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2021 Apr; 259(4):905-910. PubMed ID: 33119804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
    van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Photodynamic Therapy on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy.
    Xu Y; Su Y; Li L; Qi H; Zheng H; Chen C
    Ophthalmologica; 2017; 237(3):167-172. PubMed ID: 28171871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Noh SR; Kang MS; Kim K; Kim ES; Yu SY
    Korean J Ophthalmol; 2019 Dec; 33(6):506-513. PubMed ID: 31833247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INSTRUMENTAL DIFFERENCE IN ASSESSING CHOROIDAL HYPERPERMEABILITY AND PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Lee SM; Kwon HJ; Park SW; Lee JE; Byon IS
    Retina; 2019 Jul; 39(7):1361-1369. PubMed ID: 29554076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial.
    Zhao M; Zhang F; Chen Y; Dai H; Qu J; Dong C; Kang X; Liu Y; Yang L; Li Y; Zhou P; Pan CT; Zhang L; Liu P; Zhou H; Jiao X; Xiong Y; Tian R; Lu Y; Yu X; Li X
    JAMA Ophthalmol; 2015 Mar; 133(3):333-40. PubMed ID: 25555191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.